© 1999 Nature America Inc. • http://medicine.nature.com

CORRECTION AND ERRATUM

CORRECTION

Modulation of oncogenic potential by alternative gene use in human prostate cancer

S.S. Kadkol, J.R. Brody, J. Pevsner, J.Bai & G.R. Pasternack

Nature Med. **5**, 275–279 (1999).

On page 278, the original Fig. 3, ommitted four gap symbols and two amino-acid changes. The correct figure is shown.

```
         1                                                  50
pp32     memgrrihle lrnrtpsdvk elvldnsrsn egklegltde feeleflsti
pp32r1           s      a                      a            k
pp32r2       kw                  f    q                  l n

         51                                                100
pp32     nvgltsianl pklnklkkle lsdnrvsggl evlaekcpnl thlnlsgnki
pp32r1    g     sd     ~  r     ~~~k                   y
pp32r2    i                      s  a v              i

         101                                               150
pp32     kdlstieplk klenlksldl fncevtnlnd yrenvfkllp qltyldgydr
pp32r1              q                     g       l       scyw
pp32r2                   e      t       n  ~~~~~~~~~ ~~~~~~~~~~

         151                                               200
hpp32p   ddkeapdsda egyvegldde eededeeeyd edaqvvedee dedeeeegee
pp32r1    h    y  i  dh          g h                 g e
pp32r2   ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~

         201                                               249
hpp32p   edvsgeeeed eegyndgevd deedeeelge eergqkrkre pedegeddd
pp32r1        gd               g                  ~~ ~~~~~~~~~
pp32r2   ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~~ ~~~~~~~~~
```

ERRATUM

Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis

R.J. Moore, D.M. Owens, G. Stamp, C. Arnott, F. Burke, N. East, H. Holdsworth, L.Turner, B. Rollins, M. Pasparakis, G. Kollias & F. Balkwill

Nature Med. **5**, 828–831 (1999).

On page 829, the legend for Fig 1 was incorrect. The corrected figure and legend are shown here. We regret this error.



Fig. 1 Skin carcinogenesis in wild-type and TNF-$\alpha^{-/-}$ mice. ***a***, Initiation promotion. Mice were treated with one dose of 25 μg DMBA and then 4 μg TPA three times weekly for 15 weeks. C57Bl6/129 (■), n = 14; TNF-$\alpha^{-/-}$ (●), n = 15. ***b***, Initiation promotion. Mice were treated with one dose of 25 μg DMBA and then 4 μg TPA twice weekly for 15 weeks. Balb/c (■), n = 14; TNF-$\alpha^{-/-}$ (●), n = 13. ***c***, Complete carcinogenesis. Mice were treated with 5.1 μg DMBA twice weekly for 20 weeks. C57Bl6/129 (■), n = 15; TNF-$\alpha^{-/-}$ (●), n = 20. ***d***, Initiation promotion. Mice were treated with one dose of 25 μg DMBA and then 4 μg TPA twice weekly. C57Bl6/129 (■), n = 15; MCP-$1^{-/-}$ (●), n = 15.

© 1999 Nature America Inc. • http://medicine.nature.com